{"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"43"}],"units":"Participants"}],"groups":[{"description":"Stratum A participants had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis.","id":"BG000","title":"A: Localized Resectable Disease"},{"description":"Participants with localized unresectable primary tumors were to participate in Stratum B. No participants were enrolled to this stratum.","id":"BG001","title":"B: Localized Unresectable Disease"},{"description":"Stratum C participants had metastatic tumors.","id":"BG002","title":"C: Metastatic Tumors"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.5","value":"12.7"},{"groupId":"BG002","spread":"4.2","value":"13.3"},{"groupId":"BG003","spread":"3.6","value":"12.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"6","upperLimit":"20","value":"12"},{"groupId":"BG002","lowerLimit":"8","upperLimit":"20","value":"12"},{"groupId":"BG003","lowerLimit":"6","upperLimit":"20","value":"12"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"23"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Participants were eligible if they were ≤30 years of age on date of diagnostic biopsy confirmation of high-grade osteosarcoma or malignant fibrous histiocytoma (MFH) of bone. Participants had no previous chemotherapy or radiation therapy."}